Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma
NCT07459608
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
75
Enrollment
OTHER_GOV
Sponsor class
Conditions
Indolent Lymphoma
WM
MZL
CLL / SLL
Interventions
DRUG:
Lisaftoclax
Sponsor
Henan Cancer Hospital